Oppenheimer Asset Management Inc. Alkermes Plc. Transaction History

Oppenheimer Asset Management Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 11, 2020	SELL	$13.31 - $19.41 $13,083 - $19,080	-983 Closed	0 $0
Q1 2020 May 08, 2020	SELL	$13.06 - $21.24 $4,074 - $6,626	-312 Reduced 24.09%	983 $14,000
Q3 2019 Oct 31, 2019	BUY	$19.51 - $24.28 $4,623 - $5,754	237 Added 22.4%	1,295 $25,000
Q1 2019 Apr 24, 2019	SELL	$28.4 - $36.49 $4,004 - $5,145	-141 Reduced 11.76%	1,058 $39,000
Q4 2018 Jan 30, 2019	SELL	$27.94 - $44.61 $281,691 - $449,758	-10,082 Reduced 89.37%	1,199 $35,000
Q3 2018 Oct 26, 2018	BUY	$38.6 - $46.12 $12,506 - $14,942	324 Added 2.96%	11,281 $479,000
Q2 2018 Aug 10, 2018	SELL	$40.56 - $51.36 $395,581 - $500,914	-9,753 Reduced 47.09%	10,957 $451,000
Q1 2018 May 09, 2018	SELL	$53.61 - $67.26 $68,620 - $86,092	-1,280 Reduced 5.82%	20,710 $1.2 Million
Q3 2017 Nov 14, 2017	BUY	$49.16 - $54.45 $1.08 Million - $1.2 Million	21,990	21,990 $1.12 Million

358

180M

175K

96.6K

Ticker ALKS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 164,254,000
Market Cap $5.12B
Description
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.